The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics

Moritz Suppliet, Tomaso Duso, Annika Herr

Research output: Contribution to journalArticleScientificpeer-review

Abstract

We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 649 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of demand and, based on an oligopolistic model of multi-product firms, we then recover the marginal costs and markups. We finally evaluate the effect of the parallel imports’ policy by calculating a counter-factual scenario without parallel trade. According to our estimates, parallel imports reduce the prices for patented drugs by 11 percent and do not have a significant effect on prices for generic drugs. This amounts to an increase in the demand-side surplus by €19m per year (or €130m in total) which is relatively small compared to the average annual market size of around €227m based on ex-factory prices. The variable profits for the manufacturers of original drugs from the German market are reduced by €18m (or 37%) per year when parallel trade is allowed, yet only one third of this difference is appropriated by the importers.
Original languageEnglish
Pages (from-to)1036–1057
Number of pages21
JournalHealth Economics
Volume23
Issue number9
DOIs
Publication statusPublished - Sep 2014
Externally publishedYes

Fingerprint

Hypoglycemic Agents
Pharmaceutical Preparations
Generic Drugs
Germany
Logistic Models

Cite this

Suppliet, Moritz ; Duso, Tomaso ; Herr, Annika. / The welfare impact of parallel imports : A structural approach applied to the German market for oral antidiabetics. In: Health Economics. 2014 ; Vol. 23, No. 9. pp. 1036–1057.
@article{306aad0dbaa84162a8aaff664426064b,
title = "The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics",
abstract = "We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 649 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of demand and, based on an oligopolistic model of multi-product firms, we then recover the marginal costs and markups. We finally evaluate the effect of the parallel imports’ policy by calculating a counter-factual scenario without parallel trade. According to our estimates, parallel imports reduce the prices for patented drugs by 11 percent and do not have a significant effect on prices for generic drugs. This amounts to an increase in the demand-side surplus by €19m per year (or €130m in total) which is relatively small compared to the average annual market size of around €227m based on ex-factory prices. The variable profits for the manufacturers of original drugs from the German market are reduced by €18m (or 37{\%}) per year when parallel trade is allowed, yet only one third of this difference is appropriated by the importers.",
author = "Moritz Suppliet and Tomaso Duso and Annika Herr",
year = "2014",
month = "9",
doi = "10.1002/hec.3068",
language = "English",
volume = "23",
pages = "1036–1057",
journal = "Health Economics",
issn = "1057-9230",
publisher = "Wiley",
number = "9",

}

The welfare impact of parallel imports : A structural approach applied to the German market for oral antidiabetics. / Suppliet, Moritz; Duso, Tomaso ; Herr, Annika.

In: Health Economics, Vol. 23, No. 9, 09.2014, p. 1036–1057.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - The welfare impact of parallel imports

T2 - A structural approach applied to the German market for oral antidiabetics

AU - Suppliet, Moritz

AU - Duso, Tomaso

AU - Herr, Annika

PY - 2014/9

Y1 - 2014/9

N2 - We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 649 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of demand and, based on an oligopolistic model of multi-product firms, we then recover the marginal costs and markups. We finally evaluate the effect of the parallel imports’ policy by calculating a counter-factual scenario without parallel trade. According to our estimates, parallel imports reduce the prices for patented drugs by 11 percent and do not have a significant effect on prices for generic drugs. This amounts to an increase in the demand-side surplus by €19m per year (or €130m in total) which is relatively small compared to the average annual market size of around €227m based on ex-factory prices. The variable profits for the manufacturers of original drugs from the German market are reduced by €18m (or 37%) per year when parallel trade is allowed, yet only one third of this difference is appropriated by the importers.

AB - We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 649 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of demand and, based on an oligopolistic model of multi-product firms, we then recover the marginal costs and markups. We finally evaluate the effect of the parallel imports’ policy by calculating a counter-factual scenario without parallel trade. According to our estimates, parallel imports reduce the prices for patented drugs by 11 percent and do not have a significant effect on prices for generic drugs. This amounts to an increase in the demand-side surplus by €19m per year (or €130m in total) which is relatively small compared to the average annual market size of around €227m based on ex-factory prices. The variable profits for the manufacturers of original drugs from the German market are reduced by €18m (or 37%) per year when parallel trade is allowed, yet only one third of this difference is appropriated by the importers.

U2 - 10.1002/hec.3068

DO - 10.1002/hec.3068

M3 - Article

VL - 23

SP - 1036

EP - 1057

JO - Health Economics

JF - Health Economics

SN - 1057-9230

IS - 9

ER -